Comparison of treatment of melomental fold rhytides with cross-linked hyaluronic acid combined with onabotulinumtoxina and cross-linked hyaluronic acid alone.
BACKGROUND
Hyaluronic acid and onabotulinumtoxinA combination therapy has been shown to have greater clinical effectiveness than hyaluronic acid alone for glabellar furrowing, but this is not well documented for melomental fold rhytides.


OBJECTIVE
To compare the efficacy of intradermal cross-linked hyaluronic acid (HA) and onabotulinumtoxinA combination therapy with the efficacy of cross-linked HA monotherapy in patients with melomental fold rhytides.


METHODS
Twenty-two patients received combination therapy to a melomental fold area while also receiving cross-linked HA and a placebo saline injection to the contralateral side. Blinded physician evaluators and patient self-evaluators clinically and photographically assessed responses during standard intervals over 12 months.


RESULTS
The melomental folds treated with combination therapy had significantly greater aesthetic improvement than the monotherapy-treated side at 2 weeks and 1 month upon physician photographic review. Furthermore, the median time for return to pretreatment rhytides was 6.5 weeks longer in the combination therapy side. Patient assessment also revealed improvement over baseline for the combination therapy at 1 month.


CONCLUSIONS
Cross-linked HA and onabotulinumtoxinA combination therapy to melomental fold rhytides may provide better overall aesthetic results and longer duration of aesthetic improvement than cross-linked HA monotherapy.
Custis
Trenton
T
Division of Dermatology, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA.
Beynet
David
D
Carranza
Dafnis
D
Greco
Joseph
J
Lask
Gary P
GP
Kim
Jenny
J
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D003432:Cross-Linking Reagents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005145:Face; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007267:Injections; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D019736:Prostheses and Implants; D015361:Rhytidoplasty / Q000379:methods*; D015595:Skin Aging; D016896:Treatment Outcome
D003432:Cross-Linking Reagents; D006820:Hyaluronic Acid; D019274:Botulinum Toxins, Type A